Last reviewed · How we verify

Ethyl alcohol

South Egypt Cancer Institute · FDA-approved active Small molecule

Ethyl alcohol acts as a protoplasmic poison and denaturant that kills cancer cells through protein denaturation and cellular damage.

Ethyl alcohol acts as a protoplasmic poison and denaturant that kills cancer cells through protein denaturation and cellular damage. Used for Hepatocellular carcinoma (percutaneous ethanol injection), Tumor ablation (direct injection).

At a glance

Generic nameEthyl alcohol
Also known asChemical neuolysis
SponsorSouth Egypt Cancer Institute
Drug classCytotoxic agent / Sclerosing agent
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Ethanol denatures proteins and disrupts cellular membranes, leading to cell death. In oncology contexts, it has been used as an ablative agent for direct injection into tumors or as a sclerosing agent. The mechanism is non-selective cytotoxicity rather than targeted therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: